Summary of Runben Co., Ltd. Conference Call Company Overview - The conference call discusses Runben Co., Ltd., a company specializing in personal care products, particularly in the baby and youth skincare segments. Key Points and Arguments Sales Performance - In Q1 2025, Runben's sales data showed remarkable performance across multiple channels, with Douyin's monthly GMV growing nearly 100% year-over-year in January and exceeding 160% in February, indicating strong growth momentum [3][4] - Tmall's sales from January to February increased by approximately 38% year-over-year, reflecting a robust growth trend [4] New Product Launches - The newly launched sunscreen gel in January 2025 achieved nearly 10 million yuan in sales within two months, with GMV reaching 4.5 million yuan during the March 8th festival, outperforming competitors [4][5] - The sunscreen gel is priced at 49.9 yuan for 50ml, significantly lower than a competitor's similar product priced at 79 yuan for the same volume, showcasing Runben's competitive pricing strategy [5] Innovation and Growth in Product Lines - In 2024, Runben introduced innovative products like the timed mosquito repellent, leading to a year-over-year sales increase of over 117 times, contributing significantly to the company's performance [4][6] - The company is expanding its product line in the baby skincare category, leveraging competitive advantages through ingredient quality, collaborations, and cost-effectiveness [4][7] Market Expansion Strategies - Runben plans to enter the youth skincare market, which has significant potential due to insufficient supply. The company aims to develop age-specific products and independent brands to capture this market [4][8] - The youth skincare market is currently underserved, with a penetration rate of less than 3%, indicating substantial growth opportunities as consumer education and product offerings improve [8][9] Competitive Landscape - The youth skincare market features three main types of brands: those extending from baby care, brands targeting specific age groups, and entirely independent brands focused on youth [9][10] - The market remains unregulated and lacks clear definitions, but it is expected to grow as supply increases and concepts are better promoted [10] Innovations in Mosquito Repellent Products - Runben has established a strong online presence since 2010, leading the mosquito repellent segment. Recent innovations include smart Bluetooth mosquito repellent and timed electric mosquito repellent [11] - The company has also upgraded product ingredients, incorporating effective components like DEET in outdoor products [11] R&D and Market Insights - Runben possesses strong consumer insight capabilities, efficient R&D, and robust channel management, enabling rapid product launches and market penetration [12] - The management team is attuned to consumer habits and preferences, enhancing the company's competitive edge [12] Future Market Outlook - Despite declining birth rates, the overall baby care market is expected to grow due to the increasing focus on refined parenting concepts. The market for children aged 0-9 is substantial, with significant spending potential [13] - The market share of leading brands in China is relatively low compared to international standards, indicating room for growth in both leading brands and niche segments [13] Product and Channel Strategy for 2025 - Runben plans to launch new products in the mosquito repellent segment, including a child-lock electric mosquito repellent and various baby care items, while also expanding its offline distribution network [14] - The company aims to stabilize online growth while enhancing offline presence to mitigate risks associated with declining profits from Douyin channels [14] Profit Forecast - Projected net profits for Runben from 2024 to 2026 are 309 million, 387 million, and 480 million yuan, representing year-over-year growth rates of 36.7%, 25.3%, and 24% respectively [15] - The company is expected to continue expanding its SKU count and achieving higher growth through successful new product launches and existing product performance [15]

股票简称：润本股份 股票代码：603193 润本生物技术股份有限公司 Runben Biotechnology Co., Ltd. （广州经济技术开发区新庄五路 3 号） 首次公开发行股票主板上市公告书 保荐人（主承销商） 新疆乌鲁木齐市高新区（新市区）北京南路 358 号 大成国际大厦 20 楼 2004 室 二〇二三年十月十六日 特别提示 润本生物技术股份有限公司（以下简称"润本股份"、"发行人"、"本 公司"或"公司"）股票将于 2023 年 10 月 17 日在上海证券交易所主板上市。 本公司提醒投资者应充分了解股票市场风险以及本公司披露的风险因素， 在新股上市初期切忌盲目跟风"炒新"，应当审慎决策、理性投资。 2 第一节 重要声明与提示 一、重要声明与提示 本上市公告书部分表格中单项数据加总数与表格合计数可能存在微小差 异，均因计算过程中的四舍五入所形成。 二、风险提示 本公司提醒广大投资者注意首次公开发行股票（以下简称"新股"）上市 初期的投资风险，广大投资者应充分了解交易风险、理性参与新股交易。 具体而言，上市初期的风险包括但不限于以下几种： （一）涨跌幅限制放宽带来的股票交易风险 本公司及全体 ...

润本生物技术股份有限公司 Runben Biotechnology Co., Ltd. 首次公开发行股票并在主板上市 招股说明书 （注册稿） 本公司的发行申请尚需经上海证券交易所和中国证监会履行相应程序。本 招股说明书不具有据以发行股票的法律效力，仅供预先披露之用。投资者应当 保荐人（主承销商） 新疆乌鲁木齐市高新区（新市区）北京南路 358 号 （广州经济技术开发区新庄五路 3 号） 以正式公告的招股说明书作为投资决定的依据。 大成国际大厦 20 楼 2004 室 润本生物技术股份有限公司 招股说明书 发行人声明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发 行人注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表 明其对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保 证。任何与之相反的声明均属虚假不实陈述。 根据《证券法》规定，股票依法发行后，发行人经营与收益的变化，由发 行人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行 承担股票依法发行后因发行人经营与收益变化或者股票价格变动引致的投资风 险。 1-1-1 招股说明书 | > | | - ...

润本生物技术股份有限公司 Runben Biotechnology Co., Ltd. （广州经济技术开发区新庄五路 3 号） 首次公开发行股票并在主板上市 招股说明书 （注册稿） 本公司的发行申请尚需经上海证券交易所和中国证监会履行相应程序。本 招股说明书不具有据以发行股票的法律效力，仅供预先披露之用。投资者应当 以正式公告的招股说明书作为投资决定的依据。 保荐人（主承销商） 新疆乌鲁木齐市高新区（新市区）北京南路 358 号 大成国际大厦 20 楼 2004 室 | 发行股票类型： | 人民币普通股（A 股） | | --- | --- | | 发行股数： | 本次发行不超过 6,069.00 万股，占公司发行后总股本的 | | | 比例不低于 15%，本次发行股份均为公开发行的新股， | | | 公司原有股东不公开发售股份。 | | 每股面值： | 元人民币 1.00 | | 每股发行价格： | 【】元人民币 | | 预计发行日期： | 【】年【】月【】日 | | 拟上市的证券交易所和板块： | 上海证券交易所主板 | | 发行后总股本： | 不超过 40,459.3314 万股 | | 保荐人（主承销 ...

保荐人（主承销商） 润本生物技术股份有限公司 （广州经济技术开发区新庄五路 3 号） 首次公开发行股票并在主板上市 招股说明书 （申报稿） 本公司的发行申请尚需经上海证券交易所和中国证监会履行相应程序。本 招股说明书不具有据以发行股票的法律效力，仅供预先披露之用。投资者应当 以正式公告的招股说明书作为投资决定的依据。 新疆乌鲁木齐市高新区（新市区）北京南路 358 号 大成国际大厦 20 楼 2004 室 Runben Biotechnology Co., Ltd. 润本生物技术股份有限公司 招股说明书 发行人声明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发 行人注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表 明其对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保 证。任何与之相反的声明均属虚假不实陈述。 根据《证券法》规定，股票依法发行后，发行人经营与收益的变化，由发 行人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行 承担股票依法发行后因发行人经营与收益变化或者股票价格变动引致的投资风 险。 1-1-1 1-1-2 润本生物技术股份有 ...